Biogen Idec Inc.: PharmaVitae Profile
Datamonitor, October 2010, Pages: 92
Introduction
This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Biogen Idec's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Biogen Idec over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Biogen Idec's performance against key rivals in the prescription pharmaceutical sector
- See how the launch of company's multiple sclerosis portfolio is in transition as oral treatments become available
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Data sourcing
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Biogen Idec: PharmaVitae forecasts at a glance
Strategic insight
SWOT analysis
Chapter 3 Quarterly news update
Latest quarterly sales
Latest comment
Latest prescription pharma product news
Latest corporate news
Future product milestones
Chapter 4 Company introduction
Key findings
Background
M&A history
Current corporate structure
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Chapter 7 Key products and competitors
Key findings
Overview
Central nervous system
Oncology
Appendix
References
Abbreviations
About Datamonitor
Datamonitor consulting
Disclaimer
TABLE OF TABLES
Table 1: Biogen Idec – PharmaVitae forecasts at a glance
Table 2: Biogen Idec quarterly sales ($m), Q408–Q409
Table 3: Biogen Idec future product milestones, 2010–12
Table 4: Biogen Idec product portfolio overview ($m), 2003–09
Table 5: Biogen Idec product portfolio overview ($m), 2009–15
Table 6: Biogen Idec prescription pharmaceutical sales by therapy area ($m), 2009–15
Table 7: Biogen Idec prescription pharmaceutical sales by geographic region ($m), 2009–15
Table 8: Biogen Idec launch portfolio overview ($m), 2009–15
Table 9: Biogen Idec core portfolio overview ($m), 2009–15
Table 10: Biogen Idec expiry portfolio overview ($m), 2009–15
Table 11: Biogen Idec prescription pharmaceutical sales by molecule type ($m), 2009–15
Table 12: Biogen Idec prescription pharmaceutical sales by source ($m), 2009–15
Table 13: Total Biogen Idec sales by business unit ($m), 2003–09
Table 14: Biogen Idec operating revenue/cost analysis ($m), 2003–09
Table 15: Biogen Idec operating cost ratio analysis (% of total revenues), 2003–09
Table 16: Biogen Idec operating cost ratio analysis (% of total revenues), 2009–15
Table 17: Biogen Idec operating revenue/cost analysis ($m), 2009–15
Table 18: Key products overview
Table 19: Avonex: overview
Table 20: Avonex: sales forecast ($m), 2008–14
Table 21: Tysabri: overview
Table 22: Tysabri: sales forecast ($m), 2009–15
Table 23: Panaclar: overview
Table 24: Panaclar: sales forecast ($m), 2009–15
Table 25: Rituxan royalties: overview
Table 26: Rituxan royalties: sales forecast ($m), 2009–15
TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer
Figure 2: Biogen Idec prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15
Figure 3: Biogen Idec’s financial performance ($m), 2003–15
Figure 4: The Biogen–IDEC merger
Figure 5: Sales of Biogen Idec’s leading multiple sclerosis therapies ($m), 2002-14
Figure 6: Biogen Idec’s sales performance by key brands ($m), 2002-14
Figure 7: Biogen Idec SWOT analysis
Figure 8: Current corporate structure
Figure 9: Biogen Idec prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15
Figure 10: Key product sales ($m), 2003–15
Figure 11: Biogen Idec key sales growth drivers and resistors ($m), 2003-09
Figure 12: Biogen Idec key sales growth drivers and resistors ($m), 2009–15
Figure 13: Biogen Idec prescription pharmaceutical sales by therapy area ($m), 2003–15
Figure 14: Biogen Idec prescription pharmaceutical sales by geographic region ($m), 2003–15
Figure 15: Biogen Idec launch/core/expiry configuration ($m), 2009–15
Figure 16: Biogen Idec prescription pharmaceutical sales by molecule type ($m), 2003–15
Figure 17: Biogen Idec prescription pharmaceutical sales by source ($m), 2003–15
Figure 18: Biogen Idec operating revenue/cost analysis ($m), 2003–15
Abbott Laboratories
Amgen Inc.
AstraZeneca PLC
Cephalon
CuraGen Corporation
Elan Corporation, plc
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
IMS Health
Insight Communications Company, Inc.
Johnson & Johnson
NICE Systems Ltd
Novartis AG
Pfizer Inc
PML Microbiologicals Inc.
Safety Insurance Group, Inc.
Vernalis Group PLC
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
